PMID- 35627232
OWN - NLM
STAT- MEDLINE
DCOM- 20220531
LR  - 20220917
IS  - 2073-4425 (Electronic)
IS  - 2073-4425 (Linking)
VI  - 13
IP  - 5
DP  - 2022 May 10
TI  - Hsa_circ_0006692 Promotes Lung Cancer Progression via miR-205-5p/CDK19 Axis.
LID - 10.3390/genes13050846 [doi]
LID - 846
AB  - Circular RNA (CircRNA) is related to tumor development. Nevertheless, the 
      regulation and function of hsa_circ_0006692 and its interactions with miR-205-5p 
      and CDK19 in the development of non-small-cell lung cancer (NSCLC) were 
      un-explored. The correlations of expression levels of hsa_circ_0006692 in NSCLC 
      specimens and cells with pathological characteristics were studied. The 
      interactions of hsa_circ_0006692 with miR-205-5p and CDK19 were assessed with 
      real-time PCR, RNA-binding protein immunoprecipitation (RIP), luciferase 
      reporter, RNA pull-down, and fluorescence in situ hybridization (FISH). The roles 
      of hsa_circ_0006692 on cell growth, invasion, and migration in vitro and 
      metastasis in vivo were evaluated. Hsa_circ_0006692 was over-expressed in 60 
      cases of NSCLC specimens and cells, which was positively correlated with TNM 
      stage, tumor size, and invasion of the lung basal layer. The results of the in 
      vitro and in vivo studies revealed that the over-expression of hsa_circ_0006692 
      facilitated NSCLC cell growth, migration, and invasion, cell cycle arrest at the 
      S phase, and the activation of BCL-2, CCND1, and PCNA. The results of the 
      dual-luciferase reporter assay, RNA immunoprecipitation, and pull-down assays 
      indicated that hsa_circ_0006692 sponged miR-205-5p, which targeted CDK19 and 
      facilitated the malignant behaviors of lung cancer cells. Hsa_circ_0006692 
      modulated EMT of lung cancer cells via the stimulation of CDH1, CDH2, VIMENTIN, 
      and MMP7. This study revealed that hsa_circ_0006692 promoted NSCLC progression 
      via enhancing cell growth, invasion, and metastasis through sponging mir-205-5p, 
      up-regulating the downstream oncogene CDK19 and modulating EMT of lung cancer 
      cells. The circ-0006692/mir-205-5p/CDK19 axis might serve as a prognosis 
      biomarker and target for drugs aimed against NSCLC.
FAU - Liao, Jinrong
AU  - Liao J
AD  - Laboratory of Radiation Oncology and Radiobiology, Fujian Medical University 
      Cancer Hospital, Fujian Cancer Hospital, Fuzhou 350014, China.
FAU - Chen, Zeng
AU  - Chen Z
AD  - Laboratory of Radiation Oncology and Radiobiology, Fujian Medical University 
      Cancer Hospital, Fujian Cancer Hospital, Fuzhou 350014, China.
FAU - Luo, Xingguan
AU  - Luo X
AUID- ORCID: 0000-0003-3585-042X
AD  - Beijing Huilongguan Hospital, Peking University Huilongguan School of Clinical 
      Medicine, Beijing 100871, China.
FAU - Su, Ying
AU  - Su Y
AD  - Laboratory of Radiation Oncology and Radiobiology, Fujian Medical University 
      Cancer Hospital, Fujian Cancer Hospital, Fuzhou 350014, China.
FAU - Huang, Tao
AU  - Huang T
AUID- ORCID: 0000-0003-1975-9693
AD  - Shanghai Institute of Nutrition and Health, Chinese Academy of Sciences, Shanghai 
      200031, China.
FAU - Xu, Haipeng
AU  - Xu H
AD  - Department of Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer 
      Hospital, Fuzhou 350014, China.
FAU - Lin, Keyu
AU  - Lin K
AD  - Laboratory of Radiation Oncology and Radiobiology, Fujian Medical University 
      Cancer Hospital, Fujian Cancer Hospital, Fuzhou 350014, China.
FAU - Zheng, Qianlan
AU  - Zheng Q
AD  - Laboratory of Radiation Oncology and Radiobiology, Fujian Medical University 
      Cancer Hospital, Fujian Cancer Hospital, Fuzhou 350014, China.
FAU - Zhang, Lurong
AU  - Zhang L
AD  - Laboratory of Radiation Oncology and Radiobiology, Fujian Medical University 
      Cancer Hospital, Fujian Cancer Hospital, Fuzhou 350014, China.
FAU - Lin, Gen
AU  - Lin G
AD  - Department of Oncology, Fujian Medical University Cancer Hospital, Fujian Cancer 
      Hospital, Fuzhou 350014, China.
FAU - Lin, Xiandong
AU  - Lin X
AUID- ORCID: 0000-0002-3250-4014
AD  - Laboratory of Radiation Oncology and Radiobiology, Fujian Medical University 
      Cancer Hospital, Fujian Cancer Hospital, Fuzhou 350014, China.
AD  - Fujian Provincial Key Laboratory of Translational Cancer Medicine, Fuzhou 350014, 
      China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20220510
PL  - Switzerland
TA  - Genes (Basel)
JT  - Genes
JID - 101551097
RN  - 0 (MIRN205 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - EC 2.7.11.22 (CDK19 protein, human)
RN  - EC 2.7.11.22 (Cyclin-Dependent Kinases)
SB  - IM
MH  - *Carcinoma, Non-Small-Cell Lung/genetics
MH  - Cell Line, Tumor
MH  - Cell Movement/genetics
MH  - Cyclin-Dependent Kinases/genetics
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Lung/pathology
MH  - *Lung Neoplasms/genetics/pathology
MH  - *MicroRNAs/genetics/metabolism
PMC - PMC9141027
OTO - NOTNLM
OT  - CDK19
OT  - NSCLC
OT  - hsa_circ_0006692
OT  - mir-205-5p
OT  - regulation of cancer malignancy
COIS- The authors declare no conflict of interest.
EDAT- 2022/05/29 06:00
MHDA- 2022/06/01 06:00
PMCR- 2022/05/10
CRDT- 2022/05/28 01:15
PHST- 2022/04/12 00:00 [received]
PHST- 2022/04/27 00:00 [revised]
PHST- 2022/05/05 00:00 [accepted]
PHST- 2022/05/28 01:15 [entrez]
PHST- 2022/05/29 06:00 [pubmed]
PHST- 2022/06/01 06:00 [medline]
PHST- 2022/05/10 00:00 [pmc-release]
AID - genes13050846 [pii]
AID - genes-13-00846 [pii]
AID - 10.3390/genes13050846 [doi]
PST - epublish
SO  - Genes (Basel). 2022 May 10;13(5):846. doi: 10.3390/genes13050846.